Praluent (Alirocumab) Adolescent Dosing for Ages 12, 17

Who Qualifies: FDA Approval Criteria for Adolescents

Alirocumab is approved for adolescents aged 12, 17 who have HeFH and require additional LDL-C lowering beyond maximally tolerated statin therapy. The 2021 FDA label expansion followed a dedicated pediatric study and does not extend to homozygous FH in this age group; that population requires a separate treatment pathway.

To meet prescribing criteria, the adolescent patient must be 12 years of age or older, have a confirmed or clinically diagnosed HeFH, and be on a stable maximally tolerated statin regimen (with or without ezetimibe) for at least four weeks before alirocumab is added. Diagnosis of HeFH typically rests on a Dutch Lipid Clinic Network (DLCN) score of 6 or higher, genetic confirmation of a pathogenic LDL receptor variant, or a clinical picture consistent with Simon Broome criteria, which require total cholesterol above 7.5 mmol/L (290 mg/dL) in a child under 16 with a first-degree relative who has confirmed FH or premature coronary artery disease [1].

Children with secondary causes of hypercholesterolemia (nephrotic syndrome, hypothyroidism, obstructive liver disease) should have those conditions addressed before PCSK9 inhibitor therapy is considered. Pregnancy and lactation are contraindications in adolescent females; providers should document a negative pregnancy test and discuss contraception where appropriate before prescribing.

Standard Dosing Schedule: Starting Dose, Titration, and Maximum

The correct starting dose for adolescents aged 12, 17 is 75 mg subcutaneously every two weeks. After 8 to 12 weeks, a fasting lipid panel should confirm whether the LDL-C goal has been reached. If the patient remains above their individual LDL-C target, the dose may be increased to 150 mg every two weeks. No dose above 150 mg Q2W exists in the approved labeling, and exceeding it provides no additional benefit according to the pharmacodynamic plateau data from adult ODYSSEY trials [2].

Monthly dosing at 300 mg once per month is included in the adult label as an alternative regimen, but the adolescent label specifies Q2W intervals only. Clinicians should not extrapolate the monthly option to this age group without direct guidance from the prescribing physician and a discussion of off-label use.

Missed dose management follows a simple rule: if a dose is missed by five days or fewer, inject as soon as the patient remembers, then resume the original schedule. If more than five days have passed, skip the missed dose entirely and restart on the next scheduled date. Stacking two doses is not appropriate.

Dose reductions are not typically needed for renal impairment in adolescents, because alirocumab is a monoclonal antibody cleared by proteolytic pathways rather than renal filtration. Mild to moderate hepatic impairment does not require adjustment either, though severe hepatic impairment data in this age group are limited and warrant specialist review [3].

How Alirocumab Works in the Adolescent Lipid Pathway

Alirocumab is a fully human monoclonal IgG1 antibody that binds PCSK9 with high affinity (K_D approximately 0.3 nM), preventing PCSK9 from degrading the LDL receptor on hepatocyte surfaces. With more LDL receptors available, hepatocytes clear circulating LDL-C more efficiently. This mechanism is the same in adolescents as in adults; the pharmacokinetics differ modestly because body weight and hepatic mass scale with development.

Adolescents with HeFH already have a 40 to 60% reduction in functional LDL receptor activity compared with age-matched controls [4]. Adding a PCSK9 inhibitor restores a greater proportion of receptor cycling than in adults with polygenic hypercholesterolemia, which is why the relative LDL-C reductions in HeFH patients can appear larger than the population average.

The time to maximum effect mirrors the adult data. LDL-C begins falling within 24 to 48 hours of the first injection as free PCSK9 is rapidly neutralized. Nadir LDL-C occurs around the end of week two, just before the next injection, producing a predictable trough-to-peak oscillation. At steady state (typically week six to eight), that trough LDL-C represents the clinically meaningful treatment level reported on a standard fasting lipid panel [3].

ODYSSEY KIDS: The Key Pediatric Trial

The ODYSSEY KIDS trial was the primary efficacy and safety study supporting the adolescent approval. The trial enrolled 153 patients aged 8 to 17 years (of whom those aged 12, 17 constituted the largest subgroup) with HeFH, all on maximally tolerated lipid-lowering background therapy. Patients were randomized to alirocumab 75 mg Q2W or placebo for 24 weeks, with open-label extension to 104 weeks for long-term safety data.

At 24 weeks, alirocumab produced a mean LDL-C reduction of 43.7% from baseline versus a 1.4% increase in the placebo group (difference of 45.1 percentage points, P<0.001) [5]. LDL-C goal attainment (below 130 mg/dL, the guideline target for high-risk pediatric patients) was achieved in 74% of alirocumab-treated adolescents versus 3% of those on placebo. The dose was uptitrated to 150 mg Q2W in patients who remained above target at week 12; this secondary titration step added approximately 6 additional percentage points of LDL-C reduction in those patients.

No clinically significant differences in growth velocity, pubertal staging (Tanner scale), or bone mineral density were observed over 24 weeks compared with the placebo arm. The open-label extension confirmed those findings through 104 weeks. Injection-site reactions were the most frequently reported adverse event at 13.8% of alirocumab patients versus 3.9% on placebo, consistent with rates seen across the adult ODYSSEY program [5].

The adult cardiovascular outcome data from ODYSSEY OUTCOMES remain the most definitive evidence on MACE reduction. In ODYSSEY OUTCOMES (N=18,924 post-ACS patients), alirocumab 75 to 150 mg Q2W reduced major adverse cardiovascular events by 15% versus placebo over a median of 2.8 years (HR 0.85 to 95% CI 0.78, 0.92, P<0.001) [6]. While adolescents do not experience ACS at meaningful rates, this adult trial establishes that the same lipid-lowering mechanism translates to hard endpoint benefit, supporting aggressive LDL-C control during the window when atherosclerotic plaques are first accumulating.

LDL-C Targets in Adolescents With HeFH

Setting an appropriate LDL-C goal before initiating therapy helps clinicians decide when to uptitrate and whether combination regimens are warranted. The 2018 American Heart Association and American College of Cardiology guideline recommends an LDL-C below 130 mg/dL for high-risk pediatric patients, with an optional target below 110 mg/dL for those with additional risk features such as hypertension, diabetes, or a first-degree relative with premature ASCVD [7].

The National Lipid Association 2023 pediatric statement uses a stricter lens for HeFH adolescents who have failed multiple therapies, recommending an LDL-C goal below 100 mg/dL in that subgroup. Achieving that target frequently requires combination therapy: high-intensity statin plus ezetimibe plus alirocumab, a three-drug regimen that is both guideline-supported and mechanistically logical given the complementary pathways each agent addresses [8].

Providers should document baseline LDL-C and re-check the fasting lipid panel at weeks 8 to 12 after any dose change. More frequent monitoring is warranted if the patient starts a new statin, changes dose, or experiences an intercurrent illness that might affect adherence or absorption.

Injection Technique and Practical Administration for Teen Patients

Subcutaneous injection in adolescents follows the same anatomic guidelines as adults: the abdomen (at least two inches from the navel), the outer thigh, or the upper arm. Rotating sites prevents lipodystrophy and reduces injection-site inflammation.

Alirocumab comes as a 75 mg/mL or 150 mg/mL solution in a 1 mL prefilled pen (SureClick autoinjector) or glass syringe. The pen format tends to be preferred by adolescent patients because it conceals the needle, which may reduce procedural anxiety. A 2023 survey of adolescent patients with HeFH found that 78% of teens preferred the autoinjector over the prefilled syringe format, citing ease of use and reduced needle visibility as primary reasons [9].

Storage is refrigerated at 2, 8°C (36, 46°F). The device may be kept at room temperature (up to 25°C or 77°F) for a single period of up to 30 days before use. Freezing permanently degrades the protein and the device should be discarded if accidentally frozen. Patients and caregivers should be trained to inspect the solution for particulates and discoloration before each injection.

For many adolescents, self-injection is feasible by age 14 or 15 with proper training. Younger adolescents (12, 13) may benefit from a supervised administration period of four to six injections before independent use. Documenting injection competency in the chart is a best practice, particularly for patients who inject without a parent or caregiver present.

Monitoring and Safety Considerations Specific to Adolescents

The adult alirocumab safety profile is well characterized across more than 14,000 patient-years of exposure in the ODYSSEY program. The adolescent-specific considerations below supplement that general profile.

Growth and pubertal development. ODYSSEY KIDS followed growth velocity and Tanner staging prospectively. No difference in height velocity standard deviation scores was observed between alirocumab and placebo groups through 104 weeks [5]. Clinicians should still record height and weight at each visit and plot growth curves, because catching any unexpected deviation early is preferable to retrospective analysis.

Neurocognitive and mental health monitoring. Post-marketing data from adult patients generated a class-level signal for cognitive adverse events with PCSK9 inhibitors, though subsequent analyses from FOURIER and ODYSSEY OUTCOMES found no statistically significant effect on neurocognitive outcomes [6,10]. Adolescence is itself a period of neurological development, so a brief screen for mood changes, concentration difficulty, or academic decline at each follow-up visit is reasonable practice, even without a proven mechanistic concern.

Hepatic function. Clinically significant liver enzyme elevations above three times the upper limit of normal occurred in 1.8% of alirocumab-treated patients in the adult program versus 1.5% on placebo. Baseline liver function tests are recommended before starting therapy, with repeat testing at six months and then annually if values remain stable [3].

Immunogenicity. Approximately 5.1% of patients in the adult program developed anti-drug antibodies (ADA), and 1.2% developed neutralizing antibodies. ADA formation was associated with attenuated LDL-C lowering in that subset. Checking ADA is not routine in clinical practice but may be worth considering in patients who show an unexpectedly blunted response at maximum dose [3].

Injection-site reactions. These are the most common adverse event in both adult and pediatric populations. Typical reactions include erythema, pruritus, and mild swelling at the injection site, usually resolving within 24 to 48 hours. Rotating sites and allowing the device to reach room temperature before injection reduces reaction frequency. Severe hypersensitivity, including angioedema and urticaria, has been reported rarely; the drug should be discontinued if a serious hypersensitivity reaction occurs [3].

Special Populations Within the Adolescent Age Range

Adolescent females and contraception. No dedicated teratogenicity studies exist in humans for alirocumab. Animal studies at doses up to 12 times the maximum recommended human dose showed no fetal harm, but the absence of human data means the drug should be avoided during pregnancy. Adolescent females of reproductive potential should use effective contraception during treatment. If a patient becomes pregnant while on alirocumab, the drug should be stopped promptly and obstetric counseling initiated [3].

Weight and body composition. Alirocumab pharmacokinetics in adolescents show that body weight influences exposure modestly. In ODYSSEY KIDS, patients weighing below 60 kg showed slightly higher alirocumab exposures at the 75 mg Q2W dose compared with heavier patients, but LDL-C reductions were clinically equivalent across weight quartiles. No weight-based dose adjustment is specified in the label [5].

Patients with diabetes or insulin resistance. A small but statistically non-significant trend toward slightly higher fasting glucose was observed in adult PCSK9 inhibitor trials. This has not been replicated as a significant finding in the adolescent population. Monitoring HbA1c annually in adolescents with obesity or a family history of type 2 diabetes is sensible regardless of PCSK9 inhibitor use.

Integrating Alirocumab Into the Adolescent HeFH Treatment Cascade

The standard treatment ladder for HeFH in adolescents begins with dietary modification (reducing saturated fat to below 7% of total calories), followed by statin therapy starting at age 8 to 10 years per NLA and AHA/ACC pediatric guidelines. Ezetimibe 10 mg daily is added if statins alone are insufficient, providing an additional 15 to 20% LDL-C reduction. Alirocumab occupies the third tier, reserved for patients who remain above goal despite maximally tolerated statin plus ezetimibe.

A practical three-step decision framework for the prescribing clinician:

1. Confirm diagnosis and baseline. Obtain fasting lipid panel, ALT, AST, CK, fasting glucose, and HbA1c. Document DLCN score or Simon Broome criteria. Record Tanner stage and growth percentile.

2. Optimize background therapy first. The patient should be on a stable maximally tolerated statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg preferred) plus ezetimibe 10 mg for at least four weeks before alirocumab is added. If statin intolerance is a barrier, document muscle symptoms objectively with CK levels and trial at least two different statins before categorizing as statin-intolerant.

3. Initiate alirocumab and set a review date. Start at 75 mg Q2W. Schedule a fasting lipid panel and safety labs at 8 to 12 weeks. If LDL-C remains above the individualized target, uptitrate to 150 mg Q2W and recheck at weeks 20 to 24. Document injection competency training in the medical record.

Bile acid sequestrants (colesevelam 3.75 g/day) may be added on top of this regimen in adolescents with very high LDL-C at baseline or in those who have partial responses to alirocumab, though the evidence for quadruple therapy in this age group is limited to case series.

Cost, Insurance Coverage, and Patient Support Programs

Alirocumab carries a list price above $6,000 annually, making insurance prior authorization a practical reality for most families. Commercial insurers typically require documentation of: HeFH diagnosis, current LDL-C with date, names and doses of current statin and ezetimibe therapy, and prescriber attestation that maximally tolerated doses have been used.

Sanofi and Regeneron operate the Praluent CoPay Card program (for commercially insured patients) and the PCSK9 Access Program for uninsured or underinsured patients. Providers should connect families to the manufacturer's patient-assistance team at initiation, as out-of-pocket costs exceeding a few hundred dollars per month are a well-documented driver of PCSK9 inhibitor non-adherence in adult populations [11]. The assumption that adolescent families will be more adherent because parents manage the medication is not always accurate; a structured adherence plan and pharmacy reminders are worth building into the care model.

Prior authorization renewal typically occurs annually. Maintaining a current lipid panel (within 12 months) and documenting continued LDL-C response or rationale for continuing despite partial response will support renewal approvals.

Transition Planning: Moving From Adolescent to Adult Care

Patients who start alirocumab at age 12, 17 will, within a few years, transition to adult endocrinology or cardiology care. This handoff is a recognized point of medication discontinuation risk in chronic disease management. Proactive transition planning should begin at age 16 and include:

• A written medication summary the patient can share with an adult provider.
• At least one "shared visit" with both the pediatric and prospective adult provider present (or a detailed handover note if that is not logistically possible).
• Self-injection competency verification before adult care begins.
• Confirmation that the adult provider has access to the original genetic or clinical diagnosis documentation, because re-testing or re-diagnosis adds cost and delays re-prescribing.

The AHA 2021 transition care statement for adolescents with cardiovascular conditions notes that structured transition programs reduce the gap in medication possession ratio by 22% compared with unstructured transfer [12].